NASDAQ:VVOS Vivos Therapeutics Q1 2026 Earnings Report $0.14 -0.01 (-3.96%) As of 11:50 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vivos Therapeutics EPS ResultsActual EPS-$0.52Consensus EPS -$0.45Beat/MissMissed by -$0.07One Year Ago EPSN/AVivos Therapeutics Revenue ResultsActual Revenue$5.14 millionExpected Revenue$4.35 millionBeat/MissBeat by +$792.00 thousandYoY Revenue GrowthN/AVivos Therapeutics Announcement DetailsQuarterQ1 2026Date5/20/2026TimeAfter Market ClosesConference Call DateWednesday, May 20, 2026Conference Call Time4:00PM ETUpcoming EarningsVivos Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vivos Therapeutics Earnings HeadlinesContrasting Inspire Medical Systems (NYSE:INSP) and Vivos Therapeutics (NASDAQ:VVOS)September 22 at 5:15 AM | americanbankingnews.comEstablishment Labs (NASDAQ:ESTA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head to Head ComparisonSeptember 21 at 5:14 AM | americanbankingnews.comThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about what $375,000 did five years ago, even though no statement shows the change. Central banks have bought over 1,000 tonnes of gold a year for three straight years, using the same published data now explained in a free guide. The guide breaks down what's driving the shift in plain English, so readers can see the numbers for themselves.September 24 at 1:00 AM | American Alternative (Ad)Vivos Therapeutics Announces Material Debt ReductionSeptember 8, 2026 | globenewswire.comVivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular PartnershipAugust 28, 2026 | rttnews.comVivos Therapeutics Announces Definitive Agreements With South Palm Cardiovascular Associates to Launch South Florida Sleep & Airway Medicine CenterAugust 28, 2026 | quiverquant.comQSee More Vivos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email. Email Address About Vivos TherapeuticsVivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-disordered breathing and related airway conditions. Its approach is centered on oral appliance therapy designed to help expand or reposition the upper airway, with the goal of addressing conditions such as obstructive sleep apnea and snoring. The company’s principal product platform is the Vivos Complete Airway Repositioning and/or Expansion (CARE) system, a portfolio of customized oral appliances intended for use under the supervision of trained dental and medical professionals. Vivos also provides clinical protocols, practitioner education and treatment support through its network of affiliated providers. Vivos Therapeutics was founded in 2016 and is headquartered in Denver, Colorado. Its services are primarily offered through dental and healthcare providers in the United States, although the company has pursued broader international opportunities. The company’s products are intended to provide an alternative or complement to conventional sleep-apnea treatments such as continuous positive airway pressure therapy.View Vivos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI Infrastructure Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
